Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study;Efecto de las terapias incretínicas comparadas con pioglitazona y gliclazida en la esteatosis hepática no alcohólica de los pacientes diabéticos no controlados solo con metformina: Estudio observacional piloto

Endocrinologia y Nutricion

Volumn 63, Issue 5, 2016, Pages 194-201

  García Díaz, Eduardo ^a   Guagnozzi, Danila ^a,b   Gutiérrez, Verónica ^c   Mendoza, Carmen ^c   Maza, Cristina ^c   Larrañaga, Yulene ^c   Perdomo, Dolores ^c   Godoy, Teresa ^c   Taleb, Ghalli ^c  

^a HOSPITAL GENERAL DE LANZAROTE   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Unidad de Atención Primaria   (Spain)

Author keywords

GLP 1; Non alcoholic fatty liver disease; Thiazolidinediones

Indexed keywords

EXENDIN 4; GLICLAZIDE; INCRETIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; LIPID; PEPTIDE; VENOM;

ARTICLE; BODY WEIGHT; COMPARATIVE EFFECTIVENESS; DIABETIC PATIENT; FOLLOW UP; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PILOT STUDY; PROSPECTIVE STUDY; ULTRASOUND; WAIST CIRCUMFERENCE; AGED; BLOOD; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DIAGNOSTIC IMAGING; DRUG EFFECTS; FEMALE; LIVER FUNCTION TEST; MALE; METABOLIC SYNDROME X; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLICLAZIDE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; LIPIDS; LIRAGLUTIDE; LIVER FUNCTION TESTS; MALE; METABOLIC SYNDROME; METFORMIN; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PEPTIDES; PILOT PROJECTS; PROSPECTIVE STUDIES; SITAGLIPTIN PHOSPHATE; THIAZOLIDINEDIONES; VENOMS; WAIST CIRCUMFERENCE;

EID: 84960145748     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2016.01.006     Document Type: Article

References (30)

1. Leite N.C., Salles G.F., Araujo A.L., Villela-Nogueira C.A., Cardoso C.R. Prevalence and associated factors in non alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Liver Int. 2009, 29:113-119.
2. Ong J.P., Pitts A., Younossi Z.M. Increased overall mortality and liver related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008, 49:608-612.
3. Weiß J., Rau M., Geier A. Non-alcoholic fatty liver disease: Epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int. 2014, 111:447-452.
4. Day C.P. Non-alcoholic fatty liver disease: Current concepts and management strategies. Clin Med (Lond). 2006, 6:19-25.
5. Charlton M. Nonalcoholic fatty liver disease: A review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004, 2:1048-1058.
6. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
7. Haukeland J.W., Konopski Z., Eggesbø H.B., von Volkmann H.L., Raschpichler G., Bjøro K., et al. Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial. Scand J Gastroenterol. 2009, 44:853-860.
8. Vernon G., Baranova A., Younossi Z.M. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011, 34:274-285.
9. Blaslov K., Bulum T., Zibar K., Duvnjak L. Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol. 2014, 20:7356-7365.
10. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
11. Aguilar M., Franch-Nadal J., Font B., Gambas G. Estudio observacional transversal en consultas de atención primaria y atención hospitalaria del perfil clínico del paciente con diabetes mellitus tipo 2 no controlado en fase inicial de tratamiento (estudio EUPHORIA). Av Diabetol. 2011, 27:69-77.
12. Standards of medical care in diabetes--2014. Diabetes Care 2014, 37(Suppl 1):S14-S80. American Diabetes Association.
13. Marcuello C., Calle-Pascual A.L., Fuentes M., Runkle I., Rubio M.A., Montañez C., et al. Prevalence of the metabolic syndrome in Spain using regional cutoff points for waist circumference: The di@bet.es study. Acta Diabetol. 2013, 50:615-623.
14. Dowman J.K., Tomlinson J.W., Newsome P.N. Systematic review: The diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011, 33:525-540.
15. Saadeh S., Younossi Z.M., Remer E.M., Gramlich T., Ong J.P., Hurley M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123:745-750.
16. Angulo P., Hui J.M., Marchesini G., Bugianesi E., George J., Farrell G.C., et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45:846-854.
17. Dietrich P., Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014, 28:637-653.
18. Musso G., Gambino R., Cassader M., Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011, 43:617-649.
19. Kelley D.E., McKolanis T.M., Hegazi R.A., Kuller L.H., Kalhan S.C. Fatty liver in type 2 diabetes mellitus: Relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab. 2003, 285:E906-E916.
20. Le T.A., Loomba R. Management of non-alcoholic fatty liver disease and steatohepatitis. J Clin Exp Hepatol. 2012, 2:156-173.
21. Musso G., Cassader M., Rosina F., Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of randomized trials. Diabetologia 2012, 55:885-904.
22. Ozturk Z.A., Kadayifci A. Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. World J Hepatol. 2014, 6:199-206.
23. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008, 24:275-286.
24. Cuthbertson D.J., Irwin A., Gardner C.J., Daousi C., Purewal T., Furlong N., et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One 2012, 7:e50117.
25. Gupta N.A., Mells J., Dunham R.M., Grakoui A., Handy J., Saxena N.K., et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010, 51:1584-1592.
26. Meier J.J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012, 8:728-742.
27. Meier J.J., Gethmann A., Götze O., Gallwitz B., Holst J.J., Schmidt W.E., et al. Glucagon-like peptide 1 abolishes the posprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006, 49:452-458.
28. Seshasai S.R., Kaptoge S., Thompson A., di Angelantonio E., Gao P., Sarwar N., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011, 364:829-841.
29. Li D., Yeung S.C., Hassan M.M., Konopleva M., Abbruzzese J.L. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009, 137:482-488.
30. Martín-Domínguez V., González-Casas R., Mendoza-Jiménez-Ridruejo J., García-Buey L., Moreno-Otero R. Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease. Rev Esp Enferm Dig 2013, 105:409-420.